Joe H

Biography

As the Type 1 Diabetes (T1D) Venture Leader for the Disease Interception Accelerator (DIA), Joe Hedrick leads efforts utilizing the rapidly emerging science of immune diagnostics and precision intervention to find solutions to intercept T1D. Before joining the DIA, Joe served as Scientific Director, Cardiovascular and Metabolism Therapeutic Area (TA), where his responsibilities included initiating innovative new target programs. He also served as the Janssen Steering Committee Representative for the Accelerated Medicines Partnership with the National Institutes of Health (NIH). Prior to joining Janssen, Joe spent more than two years as Senior Director, Cure and Prevent Therapies at the JDRF, a leading non-profit T1D research organization. In this role, Joe oversaw both the immune and beta cell replacement efforts and maintained responsibility for developing and implementing JDRF’s T1D interception and biomarker strategies. Joe joins the DIA with more than 20 years of experience in both industry and non-profit drug discovery research in immunology and diabetes. He is the author of more than 50 peer-reviewed scientific articles, several book chapters and is an inventor on more than 30 patents and patent applications. Joe earned his Ph.D. from the University of California, San Diego and San Diego State University. 

Research Interest

 INFECTIOUS DISEASES